Erasca (ERAS) Faces Securities Class Action After Stock Declines 48% on Drug Safety and IP Concerns-- HBSS

SAN FRANCISCO, July 7, 2026 /PRNewswire/ -- Erasca, Inc. (NASDAQ: ERAS) faces a securities class action after the stock tanked $9.25 (-48%) on news that Revolution Medicines (RevMed) accused Erasca of patent infringement concerning Erasca's pan-RAS molecular glue targeting solid tumors...